Recombinant Anti-CD130 (gp130) antibody [EPR24557-50] (ab283685)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR24557-50] to CD130 (gp130)
- Suitable for: WB, IP
- Knockout validated
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-CD130 (gp130) antibody [EPR24557-50]
See all CD130 (gp130) primary antibodies -
Description
Rabbit monoclonal [EPR24557-50] to CD130 (gp130) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details
Unsuitable for: ICC/IF or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Wild-type A549, PC-3, Daudi, HepG2, MG-63, NIH/3T3, MEF, C6, Untreated NIH/3T3 and NIH/3T3 treated with PNGase F whole cell lysate; Mouse thymus and lung tissue lysate. IP: NIH/3T3 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR24557-50 -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab283685 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Predicted molecular weight: 104 kDa.
|
|
IP |
1/30.
|
Notes |
---|
WB
1/1000. Predicted molecular weight: 104 kDa. |
IP
1/30. |
Target
-
Function
Signal-transducing molecule. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize gp130 for initiating signal transmission. Binds to IL6/IL6R (alpha chain) complex, resulting in the formation of high-affinity IL6 binding sites, and transduces the signal. Does not bind IL6. May have a role in embryonic development (By similarity). The type I OSM receptor is capable of transducing OSM-specific signaling events. -
Tissue specificity
Found in all the tissues and cell lines examined. Expression not restricted to IL6 responsive cells. -
Sequence similarities
Belongs to the type I cytokine receptor family. Type 2 subfamily.
Contains 5 fibronectin type-III domains.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain. -
Domain
The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
The box 1 motif is required for JAK interaction and/or activation. -
Post-translational
modificationsPhosphorylation of Ser-782 down-regulates cell surface expression.
Heavily N-glycosylated. -
Cellular localization
Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3572 Human
- Entrez Gene: 16195 Mouse
- Entrez Gene: 25205 Rat
- Omim: 600694 Human
- SwissProt: P40189 Human
- SwissProt: Q00560 Mouse
- SwissProt: P40190 Rat
- Unigene: 532082 Human
see all -
Alternative names
- CD130 antibody
- CD130 antigen antibody
- CDw130 antibody
see all
Images
-
All lanes : Anti-CD130 (gp130) antibody [EPR24557-50] (ab283685) at 1/1000 dilution
Lane 1 : Wild-type A549 (human lung carcinoma epithelial cell) whole cell lysate
Lane 2 : IL6ST (CD130/gp130) knockout A549 (human lung carcinoma epithelial cell) whole cell lysate
Lane 3 : PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/50000 dilution
Predicted band size: 104 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?Blocking and diluting buffer and concentration: 5% NFDM/TBST
ab283685 was shown to specifically react with IL6ST (CD130/gp130) in wild-type A549 cells. Loss of signal was observed when knockout cell line ab266938 (knockout cell lysate ab257207) was used. Wild-type and IL6ST (CD130/gp130) knockout samples were subjected to SDS-PAGE. ab283685 and ab181602 (Rabbit anti-GAPDH loading control) were incubated for 1 hour at room temperature at 1/1000 dilution and 1/200, 000 dilution respectively. Blots were developed with Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) secondary antibody at 1/50, 000 dilution and 1/100, 000 dilution for 1 hour at room temperature before imaging. The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument using the ECL technique.
Samples are non-boiled as boiling may cause protein aggregates.
Exposure time: 70 seconds
-
All lanes : Anti-CD130 (gp130) antibody [EPR24557-50] (ab283685) at 1/1000 dilution
Lane 1 : PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate
Lane 2 : Daudi (human Burkitt's lymphoma lymphoblast) whole cell lysate
Lane 3 : HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate
Lane 4 : MG-63 (human osteosarcoma fibroblast) whole cell lysate
Lane 5 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate
Lane 6 : MEF (mouse embryonic fibroblast (immortalized)) whole cell lysate
Lane 7 : C6 (rat glial tumor glial cell) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/50000 dilution
Predicted band size: 104 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?Blocking and diluting buffer and concentration: 5% NFDM/TBST
gp130 is a glycoprotein. The molecular weight observed is consistent with what has been described in the literature (PMID: 19915009).
Low expression: Daudi (PMID: 2261637).
Samples are non-boiled as boiling may cause protein aggregates.
Exposure time: Lanes 1-2 and lane 7: 70 seconds; Lanes 3-6: 26 seconds
-
All lanes : Anti-CD130 (gp130) antibody [EPR24557-50] (ab283685) at 1/1000 dilution
Lane 1 : Mouse thymus tissue lysate
Lane 2 : Mouse lung tissue lysate
Lane 3 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate
Lane 4 : NIH/3T3 whole cell lysate treated with PNGase F
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/50000 dilution
Predicted band size: 104 kDaBlocking and diluting buffer and concentration: 5% NFDM/TBST
Samples are non-boiled as boiling may cause protein aggregates.
Exposure time: Lanes 1-2: 48 seconds; Lanes 3-4: 26 seconds.
-
CD130 (gp130) was immunoprecipitated from 0.35 mg NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 10 ug with ab283685 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab283685 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 10 ug
Lane 2: ab283685 IP in NIH/3T3 whole cell lysate
Lane 3:Rabbit monoclonal IgG (ab172730) instead of ab283685 in NIH/3T3 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 15 seconds
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (0)
ab283685 has not yet been referenced specifically in any publications.